Log in to your Inderes Free account to see all free content on this page.
Swedish Orphan Biovitrum
318.8
SEK
-1.24 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
5 following
-1.24%
+0.44%
+4.39%
+4.32%
+16.95%
+18.25%
+80.31%
+112.11%
+568.08%
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Read moreMarket cap
113.49B SEK
Turnover
33.03M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
5.2.
2025
Annual report '24
29.4.
2025
Interim report Q1'25
8.5.
2025
General meeting '24
ShowingAll content types
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB: David Meek is proposed as new Chair of the Board of Directors of Sobi
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio